The Use of Alb-PRF as a Drug Delivery System for Malignant Lesion Treatment

Authors

  • Carlos Fernando Mourão Tufts University School of Dental Medicine, Department of Periodontology, Division of Dental Research Administration. Boston, USA. https://orcid.org/0000-0001-5775-0222
  • Adam Lowenstein Tufts University School of Dental Medicine, Department of Periodontology, Division of Dental Research Administration. Boston, USA. https://orcid.org/0000-0002-0751-4894

DOI:

https://doi.org/10.32635/2176-9745.RBC.2023v69n2.3762

Keywords:

platelet-rich fibrin, drug-delivery systems, platelet-rich plasma, nanoparticles, neoplasms

Abstract

Bioengineering is an area of biotechnology that offers tools for different therapeutic strategies, including tissue therapies. For this, cells are associated with growth factors and scaffolds composed of biocompatible biomaterials capable of promoting the regeneration of tissues, such as bones. Autologous biomaterials produced from human peripheral blood have a proven ability to produce/release activating factors for tissue repair, with potential application as a vehicle for carrying substances for local release. The present idea proposes the use of a new blood-derived concentrate, Alb-PRF, an activated plasma albumin gel with the platelet-rich fibrin in the liquid phase (Liquid PRF). Alb-PRF can be able to stabilize the fibrin matrix of the scaffold, acting as a drug delivery system vehicle in malignant lesions.

Downloads

Download data is not yet available.

References

Tangen O, Berman HJ, Marfey P. Gel filtration. A new technique for separation of blood platelets from plasma. Thromb Diath Haemorrh. 1971;25(2):268-78. DOI: https://doi.org/10.1055/s-0038-1654301

Ross R, Glomset J, Kariya B, et al. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A. 1974;71(4):1207-10. doi: https://doi.org/10.1073/pnas.71.4.1207 DOI: https://doi.org/10.1073/pnas.71.4.1207

Mourão CFAB, Gheno E, Lourenço ES, et al. Characterization of a new membrane from concentrated growth factors associated with denaturized Albumin (Alb-CGF) for clinical applications: a preliminary study. Int J Growth Factors Stem Cells Dent. 2018;1(2):64-9. doi: https://doi.org/10.4103/GFSC.GFSC_21_18 DOI: https://doi.org/10.4103/GFSC.GFSC_21_18

Lourenço ES, Mourão CFAB, Leite PEC, et al. The in vitro release of cytokines and growth factors from fibrin membranes produced through horizontal centrifugation. J Biomed Mater Res A. 2018;106(5):1373-80. doi: https://doi.org/10.1002/jbm.a.36346 DOI: https://doi.org/10.1002/jbm.a.36346

Gheno E, Mourão CFAB, Mello-Machado RC, et al. In vivo evaluation of the biocompatibility and biodegradation of a new denatured plasma membrane combined with liquid PRF (Alb-PRF). Platelets. 2021;32(4):542-54. doi: https://doi.org/10.1080/09537104.2020.1775188 DOI: https://doi.org/10.1080/09537104.2020.1775188

Miron RJ, Xu H, Chai J, et al. Comparison of platelet-rich fibrin (PRF) produced using 3 commercially available centrifuges at both high (~ 700 g) and low (~ 200 g) relative centrifugation forces. Clin oral investig. 2020;24(3):1171-82. doi: https://doi.org/10.1007/s00784-019-02981-2 DOI: https://doi.org/10.1007/s00784-019-02981-2

Mourão CFAB, Mello-Machado RC, Javid K, et al. The use of leukocyte- and platelet-rich fibrin in the management of soft tissue healing and pain in post-extraction sockets: a randomized clinical trial. J Craniomaxillofac Surg. 2020;48(4):452-7. doi: https://doi.org/10.1016/j.jcms.2020.02.020 DOI: https://doi.org/10.1016/j.jcms.2020.02.020

Moraschini V, Mourão CFAB, Machado RCM, et al. Does platelet-rich fibrin decrease dimensional changes and improve postoperative comfort in post-extraction sockets? An overview of systematic reviews. Appl Sci (Basel). 2020;10(17):5750. doi: https://doi.org/10.3390/app10175750 DOI: https://doi.org/10.3390/app10175750

Ma Y, Cai F, Li Y, et al. A review of the application of nanoparticles in the diagnosis and treatment of chronic kidney disease. Bioact Mater. 2020;5(3):732-43. doi: https://doi.org/10.1016/j.bioactmat.2020.05.002 DOI: https://doi.org/10.1016/j.bioactmat.2020.05.002

Downloads

Published

2023-02-09

How to Cite

1.
Mourão CF, Lowenstein A. The Use of Alb-PRF as a Drug Delivery System for Malignant Lesion Treatment. Rev. Bras. Cancerol. [Internet]. 2023 Feb. 9 [cited 2024 Nov. 23];69(2):e-013762. Available from: https://rbc.inca.gov.br/index.php/revista/article/view/3762